Natera executive chairman sells $447k in shares By Investing.com

Matthew Rabinowitz, Executive Chairman and Director of Natera, Inc. (), sold 1,718 shares of common stock on July 27, 2026. The shares were sold at a price of $260.4908 per share, totaling $447,523.

The sale was conducted to cover tax withholding and remittance obligations related to the vesting of restricted stock units (RSUs). This transaction was made pursuant to a written instruction intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. The sale comes as Natera shares have surged 80% over the past year, though InvestingPro analysis suggests the stock is currently overvalued relative to its Fair Value—placing it among companies on the Most Overvalued list.

Following the reported transaction, Mr. Rabinowitz directly beneficially owns 2,276,125 shares of Natera common stock and indirectly owns 4,000 shares through his spouse. For deeper insights into Natera’s valuation and 10+ additional InvestingPro Tips, investors can access comprehensive analysis on the platform.

In other recent news, Natera Inc. announced that its Signatera test has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR). This certification includes the assay, specimen collection kit, and associated software, marking a significant regulatory milestone for the company. Additionally, Natera has published data in JAMA Oncology, demonstrating that its Signatera molecular residual disease test can predict chemotherapy benefits in liver cancer patients. This study involved 298 patients and was presented at the European Society for Medical Oncology Gastrointestinal Congress.

In a strategic move, Natera has partnered with Aveta Biomics for a Phase 3 clinical trial to evaluate APG-157 in patients with head and neck squamous cell carcinoma. The trial will utilize Natera’s Signatera testing to monitor molecular residual disease and treatment response. Furthermore, Bernstein SocGen Group has resumed coverage on Natera with an outperform rating, highlighting the company’s potential for increased volumes and reimbursement in minimal residual disease testing. The firm noted Japan as a key market, with expected PMDA reimbursement and a commercial launch by year-end.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.